Hypersensitivity and Infusion-Site Adverse Events with Intravenous Fosaprepitant after Anthracycline-Containing Chemotherapy: A Retrospective Study

Ralph V. Boccia(Center for Cancer and Blood Disorders), Thomas Ottoboni(Heron Therapeutics (United States)), Neil J. Clendeninn(Heron Therapeutics (United States)), Robert B. Geller

Future Oncology

October 10, 2018

10.2217/fon-2018-0662

Cited by 17

Related Papers

Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study

|Breast Cancer Research and Treatment|2017|761

Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia

|New England Journal of Medicine|2010|425

Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial

|The Lancet Oncology|2013|387

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

|The Lancet Oncology|2019|386

Molecular Gene Expression Profiling to Predict the Tissue of Origin and Direct Site-Specific Therapy in Patients With Carcinoma of Unknown Primary Site: A Prospective Trial of the Sarah Cannon Research Institute

|Journal of Clinical Oncology|2012|373